DRUG Stock News & Catalysts – Bright Minds Biosciences

FEATURED

Bright Minds Biosciences (DRUG) Securities Investigation Notice - Levi & Korsinsky

New

Bright Minds Biosciences (DRUG) shares sold off sharply as the market reacted to an FDA partial clinical hold on the planned Phase 2 BMB-101 pediatric epilepsy trial. An investigation into potential securities law

Summary

Nov 9, 2026, 10:09 AM ·PRNewswire

RECENT

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Bright Minds Biosciences (DRUG)

NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (NASDAQ:DRUG) shareholders are holding losses after the stock sold off sharply on news of an FDA partial clinical hold on the Company's planned

Nov 5, 2026, 10:07 AM ·Globe Newswire

BRIGHT MINDS BIOSCIENCES INVESTIGATION: DRUG Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Bright Minds Biosciences ("Bright Minds" or the "Company") (NASDAQ:DRUG). The

Nov 4, 2026, 2:01 PM ·Globe Newswire

DRUG Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Bright Minds Biosciences (DRUG)

NEW YORK CITY, NY / ACCESS Newswire / November 4, 2026 / Investors holding Bright Minds Biosciences (NASDAQ:DRUG) are absorbing losses after a sharp selloff triggered by the FDA's partial clinical hold on the

Nov 4, 2026, 10:10 AM ·ACCESS Newswire

DRUG SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Bright Minds Biosciences

Investors who lost money when DRUG shares sold off on the FDA's partial clinical hold for the planned Phase 2 BMB-101 epilepsy trial may have the right to seek recovery, even if they have already sold.NEW YORK, Nov.

Nov 3, 2026, 2:53 PM ·PRNewswire

Bright Minds Biosciences Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Bright Minds Biosciences (DRUG)

The FDA cited mouse toxicity findings and insufficient pharmacokinetic and juvenile-toxicity data when it placed Bright Minds' planned Phase 2 BMB-101 epilepsy trial on partial clinical hold. An investigation is

Nov 2, 2026, 6:26 PM ·PRNewswire

Bright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathies

NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces that the U.S. Food and Drug Administration ("FDA")

Nov 2, 2026, 7:30 AM ·Globe Newswire

Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a clinical stage biotechnology company focused on developing

Sep 30, 2026, 5:30 PM ·Globe Newswire

Bright Minds Biosciences to Present at Upcoming Conferences

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective

Sep 4, 2026, 4:30 PM ·Globe Newswire

Vistagen Appoints Douglas J. Williamson to its Board of Directors

SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and

Jul 31, 2026, 8:30 AM ·Globe Newswire

Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the

May 26, 2026, 7:18 PM ·Globe Newswire

Bright Minds Biosciences to Present at Upcoming Conferences

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the

Feb 25, 2026, 4:30 PM ·Globe Newswire

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945,000 common shares in the

Jan 9, 2026, 11:56 AM ·Globe Newswire

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces the pricing of its previously announced public offering of 1,945,000 common

Jan 7, 2026, 9:33 PM ·Globe Newswire

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company") announces the launch of a public offering of common shares in the capital of the

Jan 6, 2026, 4:00 PM ·Globe Newswire

Bright Minds Biosciences Inc. DRUG · News